Biodexa Pharmaceuticals (BDRX) Gross Margin (2015 - 2016)
Biodexa Pharmaceuticals' (BDRX) quarterly Gross Margin came in at 23.3% in Q4 2016, down 6706.0% year-over-year from 0.35% in Q1 2016, and down 74.21% quarter-over-quarter from 90.37% in Q4 2015.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Gross Margin (2015 - 2016) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Gross Margin across 2 years of filings, most recently posting 23.3% for Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 180.97 Bn | 177.80 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 132.56 Bn | 124.70 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 82.34 Bn | 74.34 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.73 Bn | 55.54 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 52.08 Bn | 46.95 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.90 Bn | 30.59 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.68 Bn | 29.68 Bn | 1.16 Mn | 80.31% |
| 10 | Biodexa Pharmaceuticals | 49.28 Mn | 37.93 Mn | - | - |